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Summary In order to determine the significance of local oestrogen biosynthesis within the breast, aromatase
activity has been measured in adipose tissue from the breasts of women with either benign (n=36) or
malignant breast disease (n=51). Particulate fractions from all samples possessed aromatase activity, but
levels in adipose tissue adjacent to malignant tumours were significantly higher than those in tissue close to
benign breast lesions (P<0.0001).
Elevated aromatase activity in adipose tissue from breast cancer patients may be of importance in view of
the central role played by oestrogen in the natural history of breast cancer.
Compared with other glands in the body, the adult human
breast is unique in being invested in an abundance of
adipose tissue. This is most marked in older women, the
ratio of breast adipose to glandular tissue increasing with
age (Preschtel, 1979).
The role of mammary adipose tissue is not fully
understood, but in mice the mammary fat pad appears to be
essential not only for the normal growth of the mammary
gland but also for the development of hyperplastic lesions
and cancers (De Ome et al., 1959). Since oestrogens are
heavily implicated in the aetiology of human breast cancer
(McMahon et al., 1973) it may be pertinent that adipose
tissue throughout the body is capable of synthesising
oestrogens (Nimrod & Ryan, 1975; Perel & Killinger, 1979;
Folkerd et al., 1982; Forney et al., 1981; Deslypere et al.,
1985). Factors influencing such peripheral aromatisation are
largely unknown, although levels are known to vary between
individuals and different body sites (Perel & Killinger, 1979).
The object of the present study was to measure aromatase
activity in breast adipose tissue and to compare levels in
patients with breast cancer with those in women with benign
lesions of the breast.
Materials and methods
Chemicals
1#3HA4 androstenedione was synthesised from 1#2fpHA4
androstenedione (56.0Cimmol-1, New England Nuclear)
using the method of Berkovitz et al. (1984).
Radio-inert A4 androstenedione, glucose 6 phosphate
dehydrogenase (Type XI), NAD (grade V), glucose 6
phosphate (disodium salt), ATP (disodium salt), NADP
(monosodium salt), nicotinamide and activated charcoal
were obtained from Sigma Chemical Co. Ltd., Poole, Dorset.
NE260 Scintillant was obtained from Nuclear Enterprises
Ltd., Edinburgh, and bovine serum albumin from Armour
Pharmaceuticals, Eastbourne. Other chemicals and solvents
were obtained from BDH Chemicals Ltd., Poole.
Patients
Adipose tissue was obtained from breast cancer patients
treated either by mastectomiy or wide local excision and from
patients having excision biopsies performed for benign con-
ditions. Details of the patients studied are shown in Table I.
Patients were considered to be post-menopausal if more than
3 years had elapsed since their last menstrual period. Histo-
logical details of the associated breast biopsies are given in
Table II.
Tissues
At operation adipose tissue close to the site of the breast
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Table I Details of the patients studied
Breast cancer Benign breast disease
Total 51 36
Post-menopausal 21 7
Pre- and peri-menopausal
Mean age (years) 53 (31-86) 45 (2945)
Mean weight (kg) 66 (47-89) 64 (52-71)
Table II Histology of the lesions removed from patients
Breast cancer Benign breast disease
Invasive ductal ca. 22 Benign mammary dysplasia 12
Lobular ca. 4 Fibrocystic disease 5
Mucoid ca. 4 Cyst 5
Intraduct ca/in situ ca. 3 Fibroadenoma 3
Tubular ca. 2 Fibrosis 2
Adenocarcinoma NOS 2 Sclerosing adenosis 1
Medullary ca. 1 Fat necrosis I
Spindle cell ca. 1 Within normal limits 3
Spheroidal cell ca. 1 Reduction mammoplasty 4
Invasive ca. no special
type 11
lesions was removed and transferred to the laboratory on
ice. All procedures were then performed at 4°C unless
otherwise stated. Samples were rinsed in 0.1 M phosphate
buffer before carefully dissecting adipose tissue free from any
obvious breast parenchyma or fibrous tissue. Samples were
then stored at -196°C until assayed. (Earlier experiments
confirmed that storage at this temperature did not affect
assay results.)
Preparation ofparticulatefractions ofadipose tissue
Tissue was processed according to the method of Nimrod &
Ryan (1975). Adipose tissue (2g) was homogenised by hand
in a glass-to-glass homogenizer with 2ml of 0.1 M phosphate
buffer (pH7.4) and centrifuged at 800g for 5min. The
resultant supernatant was separated from the upper layer of
solid lipid and the lower layer of cell debris using a pasteur
pipette and centrifuged at 100,000g for 1 h. The resulting
pellet (particulate fraction) was resuspended in phosphate
buffer (600p1) and assayed for aromatase activity.
Protein estimation
The protein concentration of the particulate fraction was
measured by the method of Bradford (1976). Concentrations
varied from 0.5-6.0mgml-P and no significant difference
was evident between fractions from cancer and non-cancer
patients.
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Aromatase assay
The assay was based on the measurement of 3H water
released during the conversion of 1J3HA4 androstenedione
to oestrogen (Frieden et al., 1968). [That this accurately
reflects oestrogen production was validated in 6 samples by
performing parallel incubations with [1,2,6,73H]A4 andros-
tenedione and measuring the production of radioactively
labelled oestrone and oestradiol fractions as described by
Miller et al. (1974).] Cofactors [nicotinamide (10mM), MgCl2
(5mM), glucose 6-phosphate (10mM), glucose 6-phosphate
dehydrogenase (2 uml-1) and 2 mM each ofNAD, NADP and
ATP] and substrate [100 nm 1I3HA4 androstenedione
(1 Ci)] were pre-incubated at 37'C in a total volume of
600 u1 phosphate buffer (0.1 M, pH7.4). Enzyme reactions
were started by addition of the particulate fraction (500pl) to
substrate and co-factors. Blank incubations were also set up
using 500pl of bovine serum albumin (2.0mgml-') in place
of the particulate fraction. Incubations were then performed
over 6h at 37°C with continouous shaking. Aliquots (550p1)
of the reaction mixture were removed into 3ml of ice-cold
chloroform at 3 and 6h, thoroughly shaken, and centrifuged
at 2,000g for 3min to terminate the reaction. An aliquot
(400,p1) of the resulting aqueous fraction was added to 5%
charcoal solution (800pl), mixed, and allowed to stand for
Omin with occasional further mixing. The charcoal was then
precipitated by centrifugation at 2,000g for 15min and the
supernatant decanted into a glass counting vial containing
NE260 Scintillation fluid (10ml). Radioactivity was measured
on a Packard Tri-Carb Liquid Scintillation spectrometer.
[To confirm that the radioactivity in the aqueous phase did
not represent contamination by tritiated steroids, random
aliquots from the 3 and 6h aqueous extracts were processed
and evaporated to dryness before addition of 1 ml of distilled
water and scintillation counting. These contained only
background levels of radioactivity.] Counts obtained in the
blank incubations were subtracted from all other counts
before correction for procedural losses and counting
efficiency. Results are expressed as fmol oestrogen mg
protein- I h- 1 (units) on the basis of the conversions at
3h. Reactions were usually linear for 6h, but activity
occasionally diminished between 3 and 6h.
Statistics
Statistical analyses were by the Wilcoxon rank test, and
calculation of linear correlation coefficients as appropriate.
Results
Oestrogen biosynthesis was detected in all samples of breast
adipose tissue examined with activities varying from 3.1 to
114fmol oestrogen produced mg protein-l h-1 (units). As is
shown in Figure 1 the median activity in tissue from breast
cancer patients (27.0 units) was more than two-fold higher
than that in samples from women with benign conditions
(12.3 units). The difference between the groups was
significant by the Wilcoxon Rank test (P<0.0001).
As measurements were performed on consecutive patients
from whom it was possible to obtain sufficient tissue for
analysis, the groups have not been matched in any respect
and therefore correlations have been made with other
factors which might influence oestrogen biosynthesis. The
relationship with age of the subjects is plotted separately in
Figure 2 for patients with either benign or malignant lesions.
In neither group of patients was there an obvious relation-
ship between levels of activity and age, although a tendency
was apparent for the highest levels of aromatase to be found
in breast fat from cancer patients between the ages of 40 and
55 years. The effect of menopausal status on aromatase
activity in breast fat from cancer patients is shown in Figure
3. The median value (32 units) in pre- and peri-menopausal
patients was higher than that in post-menopausal patients
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Figure 1 Aromatase activity in breast adipose tissue from
women with breast cancer (0, n=51) and women with benign
breast disease (0, n=36). The horizontal bars denote the median
activity for the two groups. The difference vetween the two
groups is significant by the Wilcoxon rank test.
(23 units), but the difference was not statistically significant.
Meaningful analysis of the benign group was not possible
because of the small number of post-menopausal women
with non-malignant breast conditions. Since there were
marked differences between the cancer and benign groups in
terms of both age and menopausal status, it was of interest
to compare results using pre-and peri-menopausal patients
only, thus minimising the age discrepancy between the
groups. As is shown in Figure 4, aromatase activity
remained significantly higher in the cancer group
(P<0.OO01).
The results were also analysed with regard to height,
weight, obesity (Quetlet index, wt/ht2), parity, age at
menarche, age at first full term pregnancy, and family
history of breast cancer but no trends were detected (results
not shown). Furthermore, in the cancer group there was no
relationship between aromatase activity and tumour type,
size, oestrogen receptor protein content or clinical stage.
Discussion
Adipose tissue is an important site of oestrogen biosynthesis
and, especially in post-menopausal women, such peripheral
activity contributes significantly to oestrogens in the
circulation (Grodin et al., 1973). However in view of the
relative abundance of adipose tissue within the breast,
oestrogen biosynthesis in mammary adipose tissue may be of
more relevance to events occuring locally within the breast.
It is pertinent therefore that the present study demonstrates
the potential for oestrogen biosynthesis in all specimens of
breast adipose tissue examined. Levels were of a similarAROMATASE ACTIVITY IN BREAST TISSUES
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Figure 2 Aromatase activity in breast adipose tissue from women with breast cancer (n=51) and women with benign breast
disease (n = 36) related to the age of the patients at the time of surgery. There is no statistically significant relationship between
age and enzyme activity for either group.
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Figure 3 Aromatase activity in breast adipose tissue from
women with breast cancer related to menopausal status (post-
menopausal >3 years since last menstruation). The horizontal
bars denote the median activity for the two groups. The
difference between the two groups is not statistically significant.
magnitude to those reported by others for adipose tissue from
various body sites (Nimrod & Ryan, 1975; Perel & Killinger,
1979; Folkerd et al., 1982; Forney et al., 1981; Deslypere et
al., 1985).
An important observation was that despite the large
variation in levels of aromatase activity between different
specimens of adipose tissue, activity was significantly higher
in tissue obtained from women with breast cancer compared
Cancer Benign
Pre- and peri-menopausal women (a- 3 yr since LMP)
Figure 4 Aromatase activity in breast adipose tissue from pre-
and peri-menopausal women with breast cancer (0, n=30) or
benign breast disease (O, n=29). The horizontal bars denote the
median activity for the two groups. The difference between the
two groups is significant by the Wilcoxon rank test.
with that in adipose tissue from women with benign lesions.
Others have failed to detect such a difference (Nimrod &
Ryan, 1975; Perel & Killinger, 1979) but have studied very
small numbers of patients. The larger study of Beranek and
co-workers (1984) also reported no significant difference
between cancer and control patients but employed less
sensitive assay conditions utilising soluble rather than par-
ticulate fractions [the latter increase the sensitivity of
Breast cancer
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aromatase assays (Nimrod & Ryan, 1975)]. Nevertheless
aromatase activity was detected in 82% of cancer cases
compared with only 50% of those with benign conditions
suggesting a trend towards enhanced aromatase activity in
adipose tissue from breast cancer patients.
There are two possible explanations for the presence of
higher aromatase in breast adipose tissue from breast cancer
patients, namely, either malignant tumours are capable of
stimulating aromatase activity in surrounding tissues or
regionally enhanced aromatase activity in adipose tissue
produces a local environment which promotes malignant
growth at that site.
With regard to the former possibility recent data suggest
that growth factors enhance aromatase activity in peripheral
tissues (McNeill et al., 1986). These include factors which
may be produced in a paracrine manner by tumours and
preliminary results indicate that the addition of extracts from
breast cancers to cultures of adipose tissue may stimulate
oestrogen biosynthesis (Reed, 1986, personal com-
munication).
Since oestrogens are heavily implicated in the promotion
of breast cancer (Lacassagne, 1932; Symmers, 1968), local
areas of enhanced oestrogen production might be expected
to encourage development of tumour foci at these favourable
sites. If this is the case one would expect a particular
association between high aromatase activity in adipose tissue
and oestrogen receptor positive tumours which are more
likely to be oestrogen responsive. However such an
association was not found in the present study.
As breast cancers in general have higher aromatase
activity than adipose tissue (Abul-Haji et al., 1979; Perel et
al., 1980) the higher activity in adipose tissue from breast
cancer patients could also be due to the presence of micro-
metastatic deposits of malignant cells within the adipose
tissue. Whilst this possibility cannot be completely excluded,
portions of fat adjacent to that used for the aromatase assay
were not shown to be involved microscopically with cancer.
Although levels of aromatase activity were higher in fat
from breast cancer patients, a large range of values was
found in patients with and without malignant breast disease.
It is clear therefore that other factors must influence the
aromatase system. Statistically significant relationships were
not observed between aromatase activity and age or
menopausal status of the patients from whom the samples
were obtained, although the highest levels of activitiy were
observed in women aged between 40 and 55. This trend is
similar to that noted in a study of abdominal adipose tissue
(Folkerd et al.,. 1982). However in view of the relative excess
of pre-menopausal women in our benign group as compared
with cancer patients and the reports of others that peripheral
aromatase increases with age (Forney et al., 1981; Cleland et
al., 1985), the data was reanalysed excluding post-
menopausal women. The difference in aromatase activity
between the cancer patients and the non-malignant group
remained highly significant, so it is therefore extremely
unlikely to be an age related phenomenon.
As we also failed to detect significant relationships
between aromatase activity and various factors associated
with excess risk of breast cancer such as height, weight,
obesity, parity, age at menarche, age at first full term
pregnancy, and family history of breast cancer, the
differences between cancer and control patients are unlikely
to be due to any excess of these risk factors in the cancer
group. Factors which influence the inherent level of
aromatase in breast adipose tissue still therefore require to
be identified. However in view of the central role of
oestrogen in both the aetiology and continued growth of
endocrine sensitive tumours, the identification of such factors
and the mechanisms by which they act may lead to the
capacity to modify the local endocrine environment within
the breast and could ultimately prove to be of value in the
clinical managment of breast cancer.
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